Glucagon and glucagon‐like peptide‐1 dual agonist therapy: A possible future towards fatty kidney disease
European Journal of Clinical Investigation · 2025
DOI: 10.1111/eci.14330 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, 2025. Verfasst von Mehmet Kanbay und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Nephrology, Koc University School of Medicine, Istanbul, Turkey. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Glucagon-Like Peptide 1, Sodium-Glucose Transporter 2 Inhibitors, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 72 Literaturangaben.
Abstract (Originalsprache)
Background Obesity is a growing epidemic affecting approximately 40% of the adult population in developed countries with major health consequences and comorbidities, including diabetes mellitus and insulin resistance, metabolically associated fatty liver disease, atherosclerotic cardiovascular and cerebrovascular diseases and chronic kidney disease. Pharmacotherapies targeting significant weight reduction may have beneficial effects on such comorbidities, though such therapeutic options are highly limited. In this narrative review, we aim to evaluate current knowledge regarding dual agonist therapies and potential implications for managing fatty kidney and chronic kidney disease. Results and Conclusion Glucagon‐like peptide‐1 agonists and sodium‐glucose cotransporter‐2 inhibitors are two novel classes of glucose‐lowering medications with potential implications and beneficiary effects on renal outcomes, including estimated glomerular filtration rate, albuminuria and chronic kidney disease progression. Recently, dual agonist therapies targeting glucagon‐like peptide‐1 and glucagon receptors, namely survodutide and cotadutide, have been evaluated in managing metabolically associated fatty liver disease, a well‐established example of visceral obesity. Fatty kidney is another novel concept implicated in the pathophysiology of chronic kidney disease among patients with visceral obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Nephrology, Koc University School of Medicine, Istanbul, Turkey.
- Department of Internal Medicine, Koç University School of Medicine, Istanbul, Turkey.
- Nephrology, Dialysis and Transplantation Unit, Grande Ospedale Metropolitano, Reggio Calabria, Italy.
- CNR-IFC, Research Unit of Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension, Institute of Clinical Physiology, Reggio Calabria, Italy.
- Renal Research Institute, New York, New York, USA.
- Institute of Molecular Biology and Genetics (Biogem), Ariano Irpino, Italy.
ORCID-Profile: Mehmet Kanbay, Carmine Zoccali
Zitieren
APA
Kanbay, M., Copur, S., Guldan, M., Ozbek, L., Mallamaci, F., & Zoccali, C. (2025). Glucagon and glucagon‐like peptide‐1 dual agonist therapy: A possible future towards fatty kidney disease. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14330
Vancouver
Kanbay M, Copur S, Guldan M, Ozbek L, Mallamaci F, Zoccali C. Glucagon and glucagon‐like peptide‐1 dual agonist therapy: A possible future towards fatty kidney disease. European Journal of Clinical Investigation. 2025. doi:10.1111/eci.14330
BibTeX
@article{Kanbay2025,
author = {Kanbay, Mehmet and Copur, Sidar and Guldan, Mustafa and Ozbek, Lasin and Mallamaci, Francesca and Zoccali, Carmine},
title = {Glucagon and glucagon‐like peptide‐1 dual agonist therapy: A possible future towards fatty kidney disease},
journal = {European Journal of Clinical Investigation},
year = {2025},
doi = {10.1111/eci.14330}
}
EUVIMED